BRADLEY STIEFEL: Open Payments
NPI 1679113989 · TIGARD, OR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,030 in 57 payments from 21 companies in 2025. Trend: 2023 $887 · 2024 $1,882 · 2025 $1,030
Food & beverage: $1,030
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 21 | $292 |
| Lundbeck LLC | 4 | $82 |
| E.R. Squibb & Sons, L.L.C. | 4 | $72 |
| Exact Sciences Corporation | 3 | $59 |
| Otsuka America Pharmaceutical, Inc. | 3 | $51 |
| Alkermes, Inc. | 2 | $50 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $49 |
| Supernus Pharmaceuticals, Inc. | 2 | $46 |
| AstraZeneca Pharmaceuticals LP | 2 | $37 |
| Exeltis, USA Inc. | 2 | $34 |
Products named: VRAYLAR, REXULTI, COBENFY, The Cologuard Plus Collection Kit, ARISTADA, CAPLYTA, QULIPTA, Qelbree.
Industry payments across OR — which companies pay providers there.
